VOLUME 3| AUGUST 2022

POPULATION HEALTH PHARMACY NEWSLETTER

In This Issue:

Page	Title
2	Upcoming Generic Drugs
4	Horizon, Cigna, Aetna Updates
7	Vaccination Updates
10	NJSBOP Updates
11	New Drug Approval
12	Epic Tool Updates*

What is new in *Population Health?*

- Pharmacy of Hope
- ACO Clinical Team Podcast
- Post Acute Opioid

Upcoming Generic Drugs

BRAND NAME	GENERIC NAME	CONDITION	DOSAGE FORM	ANTICIPATED LAUNCH
Norvir (100mg) ®	Ritonavir	Used to treat HIV infection	Capsules	2022
Combigan ®	Brimonidine Tartrate and Timolol Maleate	Used to treat glaucoma and lower high eye pressure	Solution	2022
Toviaz (4mg) ®	Fesoterodine Fumarate	Used to treat overactive bladder	Tablets	2022
Revlimid (2.5, 5, 10, 15, 20, 25mg) ®	Lenalidomide (2.5, 5, 10, 15, 20, 25mg)	Used to treat multiple myeloma, lymphoma and MDS	Capsules	March 01, 2022
Vimpat (Injection; Solution; Tablet) ®	Lacosamide	Used to treat seizures	Injection, Solution or Tablets	March 17, 2022
Zipsor ®	Diclofenac Potassium	Used to ease pain, treats arthritis	Capsules	March 24, 2022
Lexiscan Injection®	Regadenoson	Used during a stress test of the heart	Injection	April 11, 2022
Velcade Injection ®	Bortezomib	Treats multiple myeloma and a type of lymphoma	Injection	May 01, 2022
Alimta (100, 500, 750, 1000 mg)®	Pemetrexed Disodium	Used to treat lung cancer and mesothelioma	Injection	May 25, 2022
Viibryd ®	Vilazodone Hydrochloride	Used to treat low mood (depression)	Tablets	June 04, 2022
Pradaxa (75, 110, 150mg) ®	Dabigatran Etexilate Mesylate	Used to treat or prevent blood clots	Capsules	June 30, 2022
Iressa ®	Gefitinib	Treats lung cancer	Tablets	July 13, 2022
Suprep ®	Magnesium Sulfate Anhydrous; Potassium Sulfate; Sodium Sulfate	Used to clean out the GI tract	Solution	September 1, 2022
Treanda (powder and solution) ®	Bendamustine Hydrochloride	Treats a type of leukemia	Injection	December 07, 2022
Rayos (1, 2, 5 mg) ®	Prednisone	Treats inflammation of the skin, joints, lungs, and other organs	Tablets	December 23, 2022
Cambia ®	Diclofenac Potassium	Treats migraine headaches	Powder	January 1, 2023
Noxafil (injection)®	Posaconazole	Used to prevent fungal infections	Injection	January 01, 2023
Trokendi XR ®	Topiramate	Used to treat seizures, prevents migraine headaches	Capsules	January 1, 2023
Xyrem ®	Sodium Oxybate	Treats loss of muscle tone and sleepiness during the day in patients with narcolepsy	Solution	January 1, 2023
Latuda ®	Lurasidone Hydrochloride	Treats schizophrenia and low mood	Tablets	February 20, 2023

Upcoming Generic Drugs (Cont.)

Vyvanse ®	Lisdexamfetamine Dimesylate	Used to treat attention deficit problems and binge eating disorder	Capsules	February 2023
Aggrastat ®	Tirofiban Hydrochloride	Used during a heart treatment to protect the arteries	Injection	March 01,2023
Aubagio ®	Teriflunomide	Treats MS	Tablets	March 12, 2023
Gattex ®	Teduglutide Recombinant	Used to treat short bowel syndrome	Injection	March 19, 2023
Corlanor ®	Ivabradine	Used to treat heart failure	Tab & Solution	April 2023
Edurant®	Rilpivirine	Used to treat HIV	Tab	April 2023
Livalo ®	Pitavastatin Calcium	Lowers bad cholesterol and triglycerides and raises good cholesterol	Tablets	May 2, 2023
Qtern ®	Dapagliflozin/Saxagliptin	Used to lower blood sugar in patients with high blood sugar	Tablet	July 2023
Mozobil ®	Plerixafor	Used to raise the number of stem cells	Injection	July 22, 2023
Xyrem®	Sodium Oxybate	Used to treat narcolepsy	Solution	July 2023
Victoza®	Liraglutide	Used to lower blood sugar in patients with high blood sugar	Injection	December 2023



Corporate Pharmacy Services. Corporatepharmacy.com. Published 2022. Accessed June 3, 2022. https://www.corporatepharmacy.com/page/upcoming_generic_drugs

PAYER UPDATES

HORIZON

Did you know that you can see lower cost alternatives at the point of prescribing? EPIC EHR has a tool that shows patients' benefit data, costs based on their health plan, medication prices, whether prior authorization is needed and lower-cost/therapeutically equivalent alternatives. This is a great way to avoid prescription abandonment at the pharmacy.

Horizon BCBS members have a way to achieve their best health and save money on prescription medicines. Encourage patients to register for Rx Savings Solutions, a patient-facing platform, so they can see cost-saving alternatives to their existing medications. Members can sign up through the Horizon or Braven Health member portal. Once the member activates their Rx Savings Solutions account and indicates they want to switch to the lower-cost medicine, Rx Savings Solutions will work directly with the prescriber and the member's pharmacy to discuss the opportunity.

PAYER UPDATES

CIGNA

- Effective July 1, 2022,* changes have been made to commercial, Cigna Total Savings, and Legacy drug formularies as well as to the specialty medical drugs that are covered to help ensure customers have access to affordable and quality health care.
- These updates promote cost-effective and clinically appropriate therapies, coordinate treatment in the right setting, and improve clinical outcomes and affordability.
- Several egregiously priced drugs were removed from commercial, Cigna Total Savings, and Legacy formularies. This applies to the following drugs:
  - *Doxycycline hyclate* delayed release tablet (50 mg, 75 mg, 100 mg, 150 mg, and 200 mg)
  - *Mupirocin cream* (2%)
  - *Tizanidine hydrochloride* capsule (2 mg, 4 mg, and 6 mg)
  - *Epinephrine auto-injector:* The authorized generic of Adrenaclick® has been removed from our commercial and Cigna Total Savings formularies. We will make the authorized generic of Adrenaclick a nonpreferred-brand drug with quantity limits and an embedded step therapy requirement on our Legacy formulary.
  - *Insulin glargine*: BASAGLAR® has been removed from our Standard and Performance formularies. We will make SEMGLEEtm (insulin glargine-yfgn) a preferred-brand drug with quantity limits across our Standard and Performance formularies. Other formularies will continue to prefer BASAGLAR.
  - *Thyroid hormone replacement:* TIROSINT®, TIROSINT-SOL, and the authorized generic of TIROSINT have been removed from from our Advantage and Value formularies

AETNA

- High cost drugs listed under red symbol are currently not recommended to be prescribed. Clinicians are encouraged to review patient's current regimen and switch to drugs listed in yellow and green. (See Aetna formulary on next page)

Nonsteroidal anti-inflammatory agents (NSAIDs)

$ 2,418.47 Vimovo 500-20 (naproxen-esomeprazole)
$ 2,333.77 Duexis (ibuprofen-famotadine)
$ 2,229.08 Fenoprofen 200mg
$ 2,072.00 Naproxen-esomeprazole 500-20 (generic Vimovo)
$ 1,973.45 Ketoprofen cap 25mg
$ 1,949.77 Sprix spray (ketorolac)(8 day supply)
$ 1,387.79 Zipsor (diclofenac potassium)
$ 860.34 Vivlodex (meloxicam)
$ 704.60 Naprelan CR (naproxen)
$ 640.31 Zorvolex 35mg (diclofenac)
$ 525.13 Celebrex (celecoxib)
$ 463.34 Arthrotec (Diclofenac w/ Misoprostol)

$ 105.05 Diclofenac w/ Misoprostol (generic Arthrotec)
$ 74.69 Oxaprozen
$ 72.99 Ketorolac

Use this category of products to prescribe for value.

$ 60.86 Celecoxib
$ 27.68 Diclofenac potassium
$ 12.17 Sulindac
$ 12.11 Diclofenac sodium
$ 11.94 Nabumetone
$ 8.93 Ibuprofen
$ 4.37 Naproxen
$ 2.65 Meloxicam

Proton pump inhibitors

$4,098,74 Zegerid (omeprazole/NaBicarb)
$ 788.16 Omeprazole/NaBicarb (generic Zegerid)
$ 644.54 Aciphex (rabeprazole)
$ 600.66 Protonix (pantoprazole)
$ 499.39 Prevacid (lansoprazole)
$ 298.11 Dexilant (dexlansoprazole)[1]
$ 318.42 Nexium (esomeprazole)

$ 92.09 Esomeprazole (generic Nexium)
$ 71.26 Rabeprazole (generic Aciphex)

Use this category of products to prescribe for value.

$ 50.48 Lansoprazole (generic Prevacid)
$ 6.93 Pantoprazole (generic Protonix)
$ 6.87 Omeprazole (generic Prilosec)

HMG CoA-reductase Inhibitors

$ 907.60 Altoprev (lovastatin)
$ 410.95 Lipitor (atorvastatin)
$ 263.72 Crestor (rosuvastatin)
$ 209.54 Zypitamag (pitavastatin magnesium)
$ 305.51 Livalo (pitavastatin calcium)
$ 221.66 Zocor (simvastatin)

$ 132.30 Pravachol (pravastatin)

Use this category of products to prescribe for value.

$ 85.63 Fluvastatin (generic Lescol)
$ 27.27 Rosuvastatin (generic Crestor)
$ 10.07 Atorvastatin (generic Lipitor)
$ 7.28 Pravastatin (generic Pravachol)
$ 6.85 Simvastatin (generic Zocor)
$ 3.91 Lovastatin (generic Mevacor, Altoprev)

Metformin

$ 6,334.46 Glumetza
$ 1,649.12 Metformin ER-Modi (generic Glumetza)
$ 532.11 Metformin ER - Osmo Tablet (generic Fortamet)

$ 42.85 Glucophage XR

Use this category of products to prescribe for value.

$ 5.50 Metformin ER (generic Glucophage XR)
$ 4.26 Metformin tablet

PREVNAR 20

Polysaccharide Conjugate Vaccine (20-Valent)

In June 2021, FDA approved Prevnar 20, a new single-dose pneumococcal conjugate vaccine. The new guidelines by the Advisory Committee on Immunization Practices (ACIP) include Prevnar 20 as one of the recommended vaccines for adults over 18 years of age. Below is the prescribing information for Prevnar 20 in adults 65 years and older and those with underlying conditions.

New Recommendations for Adults Over 65 Years

- Adults aged ≥65 years who have not previously received a pneumococcal conjugate vaccine
- Adults aged ≥65 years whose previous vaccination history is unknown

→ 1 dose of **PCV 15** followed by 1 dose of **PPSV 23 one year later**
OR
1 dose of **PCV 20**

Kobayashi M, et al. *MMWR Morb Mortal Wkly Rep*. 2022;71(4):109-117.

Underlying Medical Conditions Ages 19-64 and Pneumococcal Conjugate Vaccine Naive

- Alcoholism or cigarette smoking
- Chronic heart, liver, lung, renal disease
- Diabetes
- Cochlear implant
- Cerebrospinal fluid leak
- Congenital or acquired asplenia
- Sickle cell or other hemoglobinopathies
- Congenital or acquired immunodeficiencies
- Generalized malignancy/cancers
  - E.g., leukemia, lymphoma, multiple myeloma, Hodgkin's
- HIV/iatrogenic immunosuppression
- Nephrotic syndrome
- Solid organ transplant

→ 1 dose of **PCV 15** followed by 1 dose of **PPSV 23 one year later**
OR
1 dose of **PCV 20**

Kobayashi M, et al. *MMWR Morb Mortal Wkly Rep.* 2022;71(4):109-117.

PREHEVBRIO

Hepatitis B Vaccine (Recombinant)

In November 2021, the FDA approved PreHevbrio, the only approved 3-antigen hepatitis B vaccine for adults in the Untied States. Guidance published by the Advisory Committee on Immunization Practices (ACIP) include PreHevbrio as one of the recommended vaccines for adults over 18 years of age for the prevention of infection in all known subtypes of hepatitis B vaccine.

Recommendations for Adults Over 18 Years

PreHevbrio is approved for adults 18 years of age and older for the prevention of infection. It is administered in a series of three doses of 1.0 mL each administered at 0,1, and 6 months.

Recommendations for Special Populations

Patients receiving chemotherapy, radiation, or high doses of corticosteroids may experience a reduce response to the PreHevbrio vaccination. As a result, consider deferring immunization for patients during time periods of severe immunosuppression.

In regards to pregnancy, there are no adequate, well-controlled studies of PreHevbrio in pregnant individuals. There is also no data available on the effects of PreHevbrio during lactation and breast-feeding.

There are no dose adjustments provided for older adult dosing, altered kidney function, or hepatic impairment.

Hepatitis B Vaccine (Trivalent [Recombinant]). Lexi-Drugs. Hudson, OH: Lexicomp, 2022. http://online.lexi.com/. Updated 5/24/22. Accessed 6/3/222
CDC. Hepatitis B Questions and Answers for Health Professionals. Centers for Disease Control and Prevention. Published March 30, 2022. Accessed June 3, 2022. https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#C15

MenQuadfi

Meningococcal Conjugate Vaccine

In April of 2020, MenQuadfi was approved by the FDA for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y for use in individuals 2 years and older. MenQuadfi is a product of Sanofi.

Sanofi Vaccine Availability Update

By mid-2022, Sanofi will only offer MenQuadfi as their meningococcal ACYW conjugate (MCV4) vaccine in place of Menactra. Menactra covered Neisseria meningitidis serogroups A, C, W, and Y as well in patients 9 months and older. Sanofi will be discontinuing its distribution of Menactra in the United States.

Sites currently using Menactra, should transition to one of the other MCV4 products available: MenQuadfi or Menveo from GSK.

Bolduc M.;7-8. Accessed July 8, 2022. https://portal.ct.gov/-/media/Departments-and-Agencies/DPH/dph/infectious_diseases/immunization/CVP-2020/2022-CVP-Communications/update-menactra-discontinuation-2-24-22.pdf

NJSBOP Updates

UPDATED GUIDANCE FOR PHARMACISTS DISPENSING OPIOID ANTIDOTES

For pharmacists dispensing an opioid antidote pursuant to a standing order, the pharmacist shall:

1. Ask if the opioid antidote is for use by the person requesting the drug or to aid someone else who is at risk.
2. If the drug is for the person making the request, then fill and document as any usual prescription, including the offer of counseling.
3. If the drug is for an entity or a person who may administer the drug in an emergency, or distribute the drug to others, the Board recommends setting up a separate profile, similar to a veterinary prescription, for "caregiver" (or other similar consistent label); alternatively, you may record the dispensation in another appropriate record or log that's readily retrievable.

Notes can be made in the profile, but the drug should not be included in any drug utilization review. Please be advised that state health plans are required by law to provide coverage for an opioid antidote without the imposition of any prior authorization or other utilization management requirements when dispensed by a licensed pharmacist under the Deputy Commissioner's standing order. For federally regulated health plans, check with the carrier to determine whether it provides coverage for opioid antidotes dispensed to third parties under the standing order before processing through insurance.

The law requires the pharmacist to comply with the Overdose Prevention Act requirements, including ensuring that overdose prevention information is provided to any person that is dispensed an opioid antidote pursuant to an individual prescription or a standing order. The overdose prevention information provided to recipients of naloxone is: https://www.njoag.gov/overdosepreventioninfo make sure to note in the profile or other appropriate record that the required information was provided with the dispensing.

Murphy P, Oliver S, Governor L, Platkin M, Fais C. UPDATED GUIDANCE for PHARMACISTS DISPENSING OPIOID ANTIDOTES. Accessed June 3, 2022. https://www.njconsumeraffairs.gov/phar/Documents/Guidance-for-Pharmacists-Dispensing-Naloxone-05262022.pdf

NOW APPROVED once weekly mounjaro™

Mounjaro® (Tirzepatide)

Introduction

Mounjaro (Tirzepatide) was recently approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Most notably, it is a first in its class medication as a a **dual-action GIP receptor AND GLP-1 receptor agonist** that increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, and slows gastric emptying.

SURPASS Trials

Mounjaro was studied in the SURPASS clinical trials, which composed of 5 different phase three trials that each had a duration of 40 weeks and in total enrolled 20,000 patients.

HBA1C Reduction: Mounjaro alone decreased HBA1C by 1.6% in comparison to placebo

Average weight loss: Patients lost 15 pounds and up to 25 pounds when put on the maximum dose of 15 mg.



A1C and Weight Change Results | MounjaroTM (tirzepatide). Mounjaro.com. Published 2021. Accessed July 22, 2022. https://www.mounjaro.com/hcp/a1c-weight#mounjaro-a1c

DOSAGE FORMS

2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg SQ injection pens.

DOSING

Start with 2.5 mg once weekly for 4 weeks, then increase to 5 mg once weekly. Once a patient has been on 5 mg once weekly, they can increase the dose by 2.5 mg/week every 4 weeks to a maximum of 15 mg.

There are no hepatic or renal dose adjustments. In pregnancy, Mounjaro can cause fetal harm. It may also decrease the efficacy of oral hormonal contraception. Patients on oral contraceptive should add a barrier method for 4 weeks after starting treatment and for 4 weeks after each dose increase. Patients can also switch to non-oral contraceptive methods.

ADVERSE REACTIONS

- Decreased appetite, diarrhea, nausea
- Use is not recommended in patients with severe GI disease

BLACK BOX WARNING

Contraindicated in patients with a personal or family history of MTC medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 (MEN 2)

Mounjaro. Lexi-Drugs. Hudson, OH: Lexicomp, 2015. http://online.lexi.com/. Updated Jun 3, 2022. Accessed Jun 24, 2022.

Epic Tool Updates

Real Time Prescription Benefits

The Real Time Prescription Benefits (RTPB) workflow allows you to create preliminary price estimates for medication orders as you place them. The RTPB can support clinicians in selecting the most cost effective medication given a patient's insurance.

Please see the link below to the knowledge builder for detailed instructions

https://bit.ly/3z32bJE